amlodipine besylate; perindopril arginine
PRESTALIA (amlodipine besylate; perindopril arginine) is perindopril, a pro-drug, is hydrolyzed to perindoprilat, which inhibits ace in humans and in animals. Approved for hypertension, to lower blood pressure. First approved in 2015.
Drug data last refreshed 4h ago · AI intelligence enriched 1mo ago
PRESTALIA is a fixed-dose combination of amlodipine besylate (a dihydropyridine calcium channel blocker) and perindopril arginine (an ACE inhibitor) for oral treatment of hypertension. It works through dual mechanisms: perindopril inhibits ACE to reduce angiotensin II-mediated vasoconstriction and aldosterone secretion, while amlodipine blocks calcium influx into vascular smooth muscle to reduce peripheral vascular resistance. This combination addresses hypertension through complementary pathways of the renin-angiotensin-aldosterone system and calcium signaling.
PRESTALIA is at peak commercial maturity with high competitive pressure (score 8/10), suggesting stable but challenged revenue environment and moderate-sized team focused on market share defense.
Perindopril, a pro-drug, is hydrolyzed to perindoprilat, which inhibits ACE in humans and in animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of the inactive decapeptide, angiotensin I, to the vasoconstrictor substance angiotensin II. Angiotensin II is a potent peripheral…
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
PRESTALIA offers career opportunities primarily in commercial execution, managed care, and brand defense rather than innovation and discovery. Working on PRESTALIA positions professionals to develop expertise in mature cardiovascular market dynamics, competitive pricing strategy, and preparation for generic transition—critical skills for managing established franchises but limited exposure to clinical development.